Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Mar;65(3):399–404. doi: 10.1038/bjc.1992.81

Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation.

B Richard 1, M C Launay-Iliadis 1, A Iliadis 1, S Just-Landi 1, D Blaise 1, A M Stoppa 1, P Viens 1, M H Gaspard 1, D Maraninchi 1, J P Cano 1, et al.
PMCID: PMC1977616  PMID: 1558794

Abstract

We have studied the pharmacokinetics of mitoxantrone in cancer patients. Two regimens were used: eight women (10 kinetics) received a 10 min i.v. infusion of 12 mg m-2 of mitoxantrone; seven women (seven kinetics) received high-dose mitoxantrone associated to high-dose alkylating agents and underwent autologous bone marrow transplantation (BMT). High-dose mitoxantrone was administered according to two different protocols. The drug was quantified in plasma with an HPLC assay and pharmacokinetic analysis was performed with the APIS software. Mitoxantrone pharmacokinetics were best described by an open two- (six kinetics) or an open three compartment model (11 kinetics). A large interindivual variability was observed in pharmacokinetic parameters. In the first group of patients, mean +/- s.d. values of clearance, half-life and total distribution volume were 21.41 +/- 14.59 1 h-1, 19.83 +/- 23.95 h, 165.89 +/- 134.75 1 respectively. In the high-dose group, these values were 21.68 +/- 7.30 1 h-1, 50.26 +/- 20.62 h, 413.70 +/- 194.81 1 respectively. Results showed that identification through the open 2-compartment model is certainly related to the small number of late time-points. We therefore think that mitoxantrone pharmacokinetics is generally best described by an open 3-compartment model. Clearance values showed that there was no saturation in mitoxantrone elimination, even at the highest doses. Terminal elimination half-life was probably underestimated because of the lack of late time-points in some kinetics. The half-life is long for patients receiving high-dose mitoxantrone (mean value was 50 h) and it would be hazardous to perform BMT too early after mitoxantrone infusion. Mitoxantrone metabolites were detected in the plasma of five patients receiving high-dose mitoxantrone and in one with hepatic impairment.

Full text

PDF
399

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts D. S., Peng Y. M., Bowden G. T., Dalton W. S., Mackel C. Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs. 1985;3(2):101–107. doi: 10.1007/BF00174156. [DOI] [PubMed] [Google Scholar]
  2. Alberts D. S., Peng Y. M., Leigh S., Davis T. P., Woodward D. L. Disposition of mitoxantrone in cancer patients. Cancer Res. 1985 Apr;45(4):1879–1884. [PubMed] [Google Scholar]
  3. Alberts D. S., Peng Y. M., Leigh S., Davis T. P., Woodward D. L. Disposition of mitoxantrone in patients. Cancer Treat Rev. 1983 Dec;10 (Suppl B):23–27. doi: 10.1016/0305-7372(83)90018-x. [DOI] [PubMed] [Google Scholar]
  4. Chiccarelli F. S., Morrison J. A., Cosulich D. B., Perkinson N. A., Ridge D. N., Sum F. W., Murdock K. C., Woodward D. L., Arnold E. T. Identification of human urinary mitoxantrone metabolites. Cancer Res. 1986 Sep;46(9):4858–4861. [PubMed] [Google Scholar]
  5. Ehninger G., Proksch B., Heinzel G., Schiller E., Weible K. H., Woodward D. L. The pharmacokinetics and metabolism of mitoxantrone in man. Invest New Drugs. 1985;3(2):109–116. doi: 10.1007/BF00174157. [DOI] [PubMed] [Google Scholar]
  6. Ehninger G., Proksch B., Heinzel G., Woodward D. L. Clinical pharmacology of mitoxantrone. Cancer Treat Rep. 1986 Dec;70(12):1373–1378. [PubMed] [Google Scholar]
  7. Ehninger G., Proksch B., Schiller E. Detection and separation of mitoxantrone and its metabolites in plasma and urine by high-performance liquid chromatography. J Chromatogr. 1985 Jul 12;342(1):119–127. doi: 10.1016/s0378-4347(00)84494-1. [DOI] [PubMed] [Google Scholar]
  8. Fountzilas G., Ohnuma T., Rammos K., Mindich B., Holland J. F. Comparison of mitoxantrone and ametantrone in human acute myelocytic leukemia cells in culture and in bone marrow granulocyte-macrophage progenitor cells. Cancer Drug Deliv. 1986 Spring;3(2):93–100. doi: 10.1089/cdd.1986.3.93. [DOI] [PubMed] [Google Scholar]
  9. Hulhoven R., Dumont E., Harvengt C. Plasma kinetics of mitoxantrone in leukemic patients. Med Oncol Tumor Pharmacother. 1984;1(3):201–204. doi: 10.1007/BF02934142. [DOI] [PubMed] [Google Scholar]
  10. Larson R. A., Daly K. M., Choi K. E., Han D. S., Sinkule J. A. A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. J Clin Oncol. 1987 Mar;5(3):391–397. doi: 10.1200/JCO.1987.5.3.391. [DOI] [PubMed] [Google Scholar]
  11. Launay M. C., Iliadis A., Richard B. Population pharmacokinetics of mitoxantrone performed by a NONMEM method. J Pharm Sci. 1989 Oct;78(10):877–880. doi: 10.1002/jps.2600781020. [DOI] [PubMed] [Google Scholar]
  12. Lenk H., Müller U., Tanneberger S. Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Res. 1987 Nov-Dec;7(6):1257–1264. [PubMed] [Google Scholar]
  13. Mulder P. O., Sleijfer D. T., Willemse P. H., de Vries E. G., Uges D. R., Mulder N. H. High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors. Cancer Res. 1989 Aug 15;49(16):4654–4658. [PubMed] [Google Scholar]
  14. Payet B., Arnoux P., Catalin J., Cano J. P. Direct determination of mitoxantrone and its mono- and dicarboxylic metabolites in plasma and urine by high-performance liquid chromatography. J Chromatogr. 1988 Feb 26;424(2):337–345. doi: 10.1016/s0378-4347(00)81110-x. [DOI] [PubMed] [Google Scholar]
  15. Richard B., Fabre G., De Sousa G., Fabre I., Rahmani R., Cano J. P. Interspecies variability in mitoxantrone metabolism using primary cultures of hepatocytes isolated from rat, rabbit and humans. Biochem Pharmacol. 1991 Jan 15;41(2):255–262. doi: 10.1016/0006-2952(91)90484-m. [DOI] [PubMed] [Google Scholar]
  16. Roboz J., Paciucci P. A., Silides D., Greaves J., Holland J. F. Detection and quantification of mitoxantrone in human organs. A case report. Cancer Chemother Pharmacol. 1984;13(1):67–68. doi: 10.1007/BF00401451. [DOI] [PubMed] [Google Scholar]
  17. Savaraj N., Lu K., Manuel V., Loo T. L. Pharmacology of mitoxantrone in cancer patients. Cancer Chemother Pharmacol. 1982;8(1):113–117. doi: 10.1007/BF00292881. [DOI] [PubMed] [Google Scholar]
  18. Savaraj N., Lu K., Valdivieso M., Burgess M., Umsawasdi T., Benjamin R. S., Loo T. L. Clinical kinetics of 1, 4-dihydroxy-5,8-bis [(2-[(2-hydroxyethyl) amino] ethyl] amino ]-9, 10-anthracenedione. Clin Pharmacol Ther. 1982 Mar;31(3):312–316. doi: 10.1038/clpt.1982.39. [DOI] [PubMed] [Google Scholar]
  19. Shenkenberg T. D., Von Hoff D. D. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med. 1986 Jul;105(1):67–81. doi: 10.7326/0003-4819-105-1-67. [DOI] [PubMed] [Google Scholar]
  20. Smyth J. F., Macpherson J. S., Warrington P. S., Leonard R. C., Wolf C. R. The clinical pharmacology of mitozantrone. Cancer Chemother Pharmacol. 1986;17(2):149–152. doi: 10.1007/BF00306744. [DOI] [PubMed] [Google Scholar]
  21. Stewart D. J., Green R. M., Mikhael N. Z., Montpetit V., Thibault M., Maroun J. A. Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep. 1986 Nov;70(11):1255–1261. [PubMed] [Google Scholar]
  22. Van Belle S. J., de Planque M. M., Smith I. E., van Oosterom A. T., Schoemaker T. J., Deneve W., McVie J. G. Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. Cancer Chemother Pharmacol. 1986;18(1):27–32. doi: 10.1007/BF00253059. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES